CapsoVision, Inc. Form 8-K Summary
Business Context and Reporting Period
CapsoVision, Inc. (Nasdaq: CV), a Delaware corporation, filed this Current Report on Form 8-K on December 29, 2025. The report addresses a specific corporate event occurring on the same date.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report focused on a regulatory submission event rather than financial performance.
Material Changes
The material event reported is the submission of a 510(k) application to the U.S. Food and Drug Administration (FDA). This application concerns the Company's proprietary AI-assisted module for its CapsoCam Plus® product.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the regulatory submission itself. The press release detailing the submission is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the status and expected timeline of the FDA 510(k) review for the AI-assisted module.
- Review the full text of the press release (Exhibit 99.1) for specific details on the AI module's capabilities.
- Check subsequent filings for FDA determination results (approval or request for additional information).
- Confirm the impact of this regulatory milestone on the Company's commercialization strategy for CapsoCam Plus®.